Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "Reddy Laboratories" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about Reddy Laboratories for you to read. Along with our medical data and news we also list Reddy Laboratories Clinical Trials, which are updated daily. BioPortfolio also has a large database of Reddy Laboratories Companies for you to search.
Under the terms of the agreement, Dr. Reddy’s sold all the issued and outstanding membership interests in Dr. Reddy’s Laboratories Tennessee, LLC and certain related assets. Dr. Reddy’s The post Dr. Reddy’s Laboratories sells antibiotic manufacturing site in Bristol, Tennessee appeared first on Pharma Business review.
NEW DELHI (dpa-AFX) - Dr. Reddy's Laboratories Ltd. (RDY), along with its subsidiaries, announced the termination of the license granted to Armis Biopharma, Inc. for its investigational antibacter...
NewsDr. Reddy’s Laboratories has launched Hervycta, a biosimilar of Roche’s Herceptin, in India, indicated for the treatment of HER2-positive cancers (early breast cancer, metastatic breast cancer, and metastatic gastric cancer).
Dr. Reddy’s Laboratories has signed a distribution agreement with UCB to supply the latter’s epilepsy drug Briviact in India. As...Read More... The post Deals this week: Dr. Reddy’s Laboratories, Pluristem Therapeutics, Fortress Biotech appeared first on Pharmaceutical Technology.
NewsDr. Reddy's Laboratories announces final approval and launch of Buprenorphine and Naloxone Sublingual Film in the U.S. market.
Dr. Reddy’s Laboratories Ltd.INVESTOR RELATIONSSAUNAK SAVLA, +firstname.lastname@example.orgMEDIA RELATIONSCALVIN PRINTER, +email@example.com Read more...
Dr Reddy's Laboratories, a Rs. 14,200 crore plus fifth largest Indian phrma major, has posted growth in net profit during the first quarter ended June 2018 on account of launch of new product in US and emerging markets.
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that following the launch of its generic Buprenorphine and Naloxone Sublingual Film in the U.S. Market, the U.S. District Court for the District … Continue reading → Cet article Dr. Reddy’s Laboratories defends its right to lau...
Dr. Reddy's Laboratories' Aspirin and Extended-Release Dipyridamole capsules was granted approval by the FDA. -More-
India’s Dr Reddy’s Laboratories has announced the filing of New Drug Application (NDA) for its migraine…
Dr. Reddyâs Laboratories has announced receipt of a US FDA establishment inspection report regarding two active pharmaceutical ingredient plants in Hyderabad, India.
Dr. Reddy's Laboratories Limited Strategy, SWOT and Corporate Finance ReportSummaryDr. Reddy's Laboratories Limited Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.Key HighlightsDr. Re...
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has received final approval from the U.S. Food and Drug Administration (USFDA) and is launching Buprenorphine and Naloxone Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, a therapeutic equivalent …
Dr. Reddyâs Laboratories has announced its biosimilar version of Rocheâs Herceptin, Hervycta (trastuzumab), is now available on the Indian market.
UCB has granted Dr. Reddy's Laboratories exclusive rights to market Briviact, or brivaracetam, in India. -More-
The US FDA has announced that over 236,000 bottles of statins will be voluntarily recalled by Dr. Reddyâs Laboratories, after issues were found with impurities.
India’s Dr. Reddy's Laboratories has entered a definitive agreement to sell its API manufacturing business unit at Jeedimetla, Hyderabad, Pakistan, to Therapiva Private Ltd, an emerging generics pharmaceutical company headquartered in Abu Dhabi, United Arab Emirates.
NEW DELHI (dpa-AFX) - Dr. Reddy's Laboratories Ltd. (RDY) announced the launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, an over-the-counter therapeutic equivalent generic ver...
Indian pharmaceutical company Dr Reddy’s Laboratories has announced that the US District Court in New Jersey has issued a temporary restraining...Read More... The post US court issues a restraint order against Dr Reddy’s new drug appeared first on Pharmaceutical Technology.
Dr Reddy's Laboratories (DRL), a Rs. 14,200 crore plus pharma major, has suffered another setback during the fourth quarter ended March 2018 on account of stagnant sales, significant higher tax provisions, price erosion
Indivior has requested a temporary restraining order against Dr. Reddyâs Laboratories to prevent further sales of its generic buprenorphine and naloxone sublingual film product in the US.
Migraine sufferers could have a new treatment option. India-based Dr. Reddy’s Laboratories and its subsidiary Promius Pharma, LLC filed a NDA with the U.S. FDA for approval of migraine candidate DFN-02.
NEW DELHI (dpa-AFX) - Dr. Reddy's Laboratories Ltd. (RDY) on Wednesday announced the launch of Neostigmine Methylsulfate Injection, USP, a therapeutic equivalent generic version of Bloxiverz or Ne...
Dr Reddy’s Laboratories has set in motion significant cost control initiatives as part of broader efforts to emerge leaner and...
Shares of Dr. Reddy’s Laboratories Ltd. are surging this morning after the FDA approved its generic version of Suboxone (buprenorphine and naloxone) sublingual film for opioid addiction.